- Home
- SLQT vs CRGX Comparison
SLQT vs CRGX Comparison
Compare SLQT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLQT
- CRGX
- Stock Information
- Founded
- SLQT 1999
- CRGX 2021
- Country
- SLQT United States
- CRGX United States
- Employees
- SLQT N/A
- CRGX N/A
- Industry
- SLQT Specialty Insurers
- CRGX
- Sector
- SLQT Finance
- CRGX
- Exchange
- SLQT Nasdaq
- CRGX Nasdaq
- Market Cap
- SLQT 682.6M
- CRGX 621.4M
- IPO Year
- SLQT 2020
- CRGX 2023
- Fundamental
- Price
- SLQT $4.46
- CRGX $13.84
- Analyst Decision
- SLQT Hold
- CRGX Strong Buy
- Analyst Count
- SLQT 1
- CRGX 6
- Target Price
- SLQT $4.00
- CRGX $31.80
- AVG Volume (30 Days)
- SLQT 1.2M
- CRGX 228.3K
- Earning Date
- SLQT 02-05-2025
- CRGX 03-20-2025
- Dividend Yield
- SLQT N/A
- CRGX N/A
- EPS Growth
- SLQT N/A
- CRGX N/A
- EPS
- SLQT N/A
- CRGX N/A
- Revenue
- SLQT $1,381,309,000.00
- CRGX N/A
- Revenue This Year
- SLQT $12.73
- CRGX N/A
- Revenue Next Year
- SLQT $14.03
- CRGX N/A
- P/E Ratio
- SLQT N/A
- CRGX N/A
- Revenue Growth
- SLQT 28.72
- CRGX N/A
- 52 Week Low
- SLQT $1.08
- CRGX $10.91
- 52 Week High
- SLQT $4.62
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- SLQT 70.77
- CRGX 49.08
- Support Level
- SLQT $4.21
- CRGX $10.91
- Resistance Level
- SLQT $4.62
- CRGX $15.75
- Average True Range (ATR)
- SLQT 0.31
- CRGX 1.14
- MACD
- SLQT 0.02
- CRGX 0.13
- Stochastic Oscillator
- SLQT 85.84
- CRGX 59.55
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.